✚
RA
Research concept · Proposed collaboration: dBme Research Group • Proposed pilot: Asperia Healthcare Limited
RAPID AMR WORKFLOW

Earlier answers. Better decisions.

Fast PCR screening. Targeted sequencing. A clearer path to review.

SCREENING TARGET2 hours

vs. 48–72h conventional AST

৳
ESTIMATED CASE FEE৳1,200

No sequencing add-on

CURRENT ROUTEFast track

Screening-first approach

ACTIVE SPECIMEN

GAMR-BD-001 Fast-track MBL

Klebsiella pneumoniae (ST11) · 68M · endotracheal aspirate

LoadingMeropenem · empirical therapy

qPCR / Stage 2

● Local-first demo

Amplification, made visible

40 thermal cycles · synthetic logistic fluorescence · Ct is an input, not a fitted threshold crossing

● 16S rRNA● blaNDM● blaCTX-M● rmtB
Positive <35 · Borderline 35–38 · Negative >38. Adjusting the display threshold does not change the entered Ct.

96-well plate

Internal control passed • synthetic melt peak 84.2°C

Synthetic melt-curve Tm table
TargetTm (°C)
16S rRNA80.0
blaNDM80.7
blaCTX-M81.4
rmtB82.1

Illustrative peaks; assay-specific validation pending.

10 multiplex target groups
  • 16S rRNA + species
  • blaNDM-1/5
  • blaOXA-48/181/232
  • blaKPC-2
  • blaCTX-M-15/9
  • blaSHV / blaTEM
  • qnrB/qnrS + aac(6′)-Ib-cr
  • rmtB/armA/aadB
  • sul1/dfrA
  • mcr-1

Target calls LIVE DEMO CONTROLS

POSITIVE
POSITIVE
NEGATIVE
NEGATIVE
POSITIVE
NEGATIVE
NEGATIVE
NEGATIVE
NEGATIVE
NEGATIVE
POSITIVE
NEGATIVE
NEGATIVE
NEGATIVE
NEGATIVE
NEGATIVE
⚡ Instant Demo Scenario Controller

Synthetic cases • gene and mutation controls are available in qPCR and Sanger.

GenAMR · Research demo · No external AI services